Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Insider Trading Alert: Stacy Markel, Chief People Officer of Nuvation Bio (NUVB), purchased 10,000 shares of Class A Common Stock on June 18, 2025, at a price of $1.71 per share, representing a total investment of $17,100.
Following this transaction, Markel now holds 29,591 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed as a direct ownership transaction.
This insider buying activity by a key executive officer could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with SEC regulations, with the filing submitted through an attorney-in-fact, Stephen Dang.
Nuvation Bio CFO Philippe Sauvage reported two insider purchase transactions of Class A Common Stock:
- On June 16, 2025: Acquired 3,300 shares at $1.835 per share
- On June 17, 2025: Acquired 4,000 shares at $1.79 per share
Following these transactions, Sauvage's direct ownership increased to 9,902 shares. The filing notes that his holdings include 2,602 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. These insider purchases by the CFO, totaling 7,300 shares over two consecutive days, may signal management's confidence in the company's valuation and future prospects.
Insider Purchase Alert: Colleen Sjogren, Chief Commercial Officer of Nuvation Bio (NUVB), has acquired 50,000 shares of Class A Common Stock on June 16, 2025, at a weighted average price of $1.807 per share, representing a total investment of approximately $90,350.
Following this transaction, Sjogren now beneficially owns 81,000 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed in multiple transactions with prices ranging from $1.795 to $1.82 per share.
This insider purchase by a senior executive could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with securities regulations, with the filing submitted through an attorney-in-fact on June 18, 2025.
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), reported significant insider purchases on June 16, 2025. The transactions involved:
- First purchase: 26,000 shares of Class A Common Stock at $1.79 per share
- Second purchase: 24,000 shares of Class A Common Stock at $1.80 per share
Following these transactions, Wentworth directly owns a total of 50,000 shares of Class A Common Stock. The insider's substantial purchase of shares, totaling approximately $89,740, could signal confidence in the company's future prospects. The Form 4 was filed through an attorney-in-fact, Stephen Dang, on June 18, 2025.
David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.
Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.
Key transaction details:
- Transaction type: Direct purchase of common stock
- Total transaction value: ~$893,500
- Filing was signed by Stephen Dang as attorney-in-fact
- No derivative securities were involved in this transaction